Zacks Research Forecasts Alkermes’ Q2 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Investment analysts at Zacks Research dropped their Q2 2025 EPS estimates for shares of Alkermes in a report released on Monday, January 6th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.31 for the quarter, down from their previous estimate of $0.33. The consensus estimate for Alkermes’ current full-year earnings is $2.25 per share. Zacks Research also issued estimates for Alkermes’ Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at $0.35 EPS and FY2026 earnings at $1.56 EPS.

Several other analysts have also recently commented on ALKS. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and upped their target price for the company from $25.00 to $36.00 in a research report on Tuesday, November 5th. JPMorgan Chase & Co. dropped their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Mizuho raised their target price on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. Finally, The Goldman Sachs Group cut their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $36.00.

Alkermes Price Performance

Shares of ALKS stock opened at $28.42 on Wednesday. The firm has a market cap of $4.60 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.03 and a beta of 0.49. Alkermes has a 12 month low of $22.90 and a 12 month high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The stock has a 50-day moving average price of $29.26 and a 200 day moving average price of $27.64.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 61,151 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $32.07, for a total transaction of $1,961,112.57. Following the transaction, the executive vice president now directly owns 47,576 shares of the company’s stock, valued at approximately $1,525,762.32. This represents a 56.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the transaction, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. This represents a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 147,738 shares of company stock worth $4,572,904 in the last quarter. 4.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Diversified Trust Co raised its position in Alkermes by 11.5% in the fourth quarter. Diversified Trust Co now owns 42,509 shares of the company’s stock worth $1,223,000 after acquiring an additional 4,378 shares during the period. Franklin Resources Inc. raised its holdings in shares of Alkermes by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 120,006 shares of the company’s stock worth $3,486,000 after purchasing an additional 2,903 shares during the period. Tidal Investments LLC bought a new stake in shares of Alkermes in the 3rd quarter worth approximately $1,098,000. Wilmington Savings Fund Society FSB purchased a new position in Alkermes in the third quarter valued at approximately $582,000. Finally, Sanctuary Advisors LLC grew its holdings in Alkermes by 254.5% during the third quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock valued at $944,000 after purchasing an additional 23,541 shares during the period. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.